Philadelphia, PANCT07554560Now EnrollingIRB Ready

Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trial in Philadelphia, PA

Access cutting-edge pancreatic ductal adenocarcinoma (pdac) treatment through this clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.

Sponsored by Children's Hospital of Philadelphia

Quick Self-Assessment

See if you qualify for this Philadelphia location

Preparing your pre-screening questions…

Expert Care in Philadelphia

Access pancreatic ductal adenocarcinoma (pdac) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic ductal adenocarcinoma (pdac) treatment provided free

Apply for This Philadelphia Location

Check if you qualify for this pancreatic ductal adenocarcinoma (pdac) clinical trial in Philadelphia, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Philadelphia

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Philadelphia site if eligible
  4. 4Begin participation

About This Pancreatic Ductal Adenocarcinoma (PDAC) Study in Philadelphia

Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to gastrointestinal (GI) symptoms, malnutrition, weight loss, and reduced quality of life (QoL). Current standard treatment, pancreatic enzyme replacement therapy (PERT), is limited by suboptimal adherence, high cost, and partial effectiveness to prevent fat malabsorption. The objective of the study is to assess the feasibility and maintenance of lipid absorption function of a structured lipid medical food (SLMF; Encala®) powder in subjects with PDAC and NET with EPI.

Sponsor: Children's Hospital of Philadelphia

Who Can Participate

Inclusion Criteria

Pancreatic ductal adenocarcinoma or pancreatic neuroendocrine tumor diagnosis and age greater than or equal to 18 years
Life expectancy of 4 months or greater
Oral or enteral tube feeding for \> 60% daily calories
For patients with NET, evidence of GI dysfunction such as \>5% unintentional weight loss, increased number of bowel movements¸change in stool consistency (e.g., soft stool or diarrhea), as documented in the medical record and confirmed by the treating oncologist.

Exclusion Criteria

Pregnant or lactating
Unable to consume food by mouth (oral intake)
Allergy to soy lecithin product ingredients
Psychosocial environment for which study participation may be difficult for subject or family, as confirmed by medical team
Military service members, Reserve Service members, National Guard members, Department of Defense (DoD) civilians, and DoD contractors
Patients with diminished capacity to consent

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Philadelphia?

Yes, this clinical trial (NCT07554560) has an active research site in Philadelphia, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Ductal Adenocarcinoma (PDAC) Treatment Options in Philadelphia, PA

If you're searching for pancreatic ductal adenocarcinoma (pdac) treatment options in Philadelphia, PA, this clinical trial (NCT07554560) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Philadelphia research site is actively enrolling participants for this clinical trial. You'll receive care from experienced pancreatic ductal adenocarcinoma (pdac) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic ductal adenocarcinoma (pdac) clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in Philadelphia, PA

See all pancreatic cancer clinical trials recruiting in Philadelphia — not just this study.

Browse Pancreatic Cancer Trials in Philadelphia

Ready to Join in Philadelphia?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Philadelphia, PA